William F. Hahne

Proglumide and benzotript: members of a different class of cholecystokinin receptor antagonists.

William F. Hahne, Robert T. Jensen, George F. Lemp et al. · Proceedings of the National Academy of Sciences · 1981 · 237 citations · Full text

Gastrointestinal Pharmacology, Pharmacotherapy, Experimental Pharmacology +16

Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group.

Paul J. Hesketh, Rudolph M. Navari, Thomas Grote et al. · Journal of Clinical Oncology · 1996 · 148 citations

Single-Blind Study of the Effects of Intravenous Dolasetron Mesylate Versus Ondansetron on Electrocardiographic Parameters in Normal Volunteers

Claude R. Benedict, Robert Arbogast, Lorene A. Martin et al. · Journal of Cardiovascular Pharmacology · 1996 · 104 citations

Treatment parameters modulating regression of human melanoma xenografts by an antibody–drug conjugate (CR011-vcMMAE) targeting GPNMB

Vincent A. Pollack, Enrique Álvarez, Kam Fai Tse et al. · Cancer Chemotherapy and Pharmacology · 2007 · 82 citations

Antibody–drug Conjugate, Tumor Biology, Drug Targeting +12

Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.

Mark G. Kris, Steven M. Grunberg, R J Gralla et al. · Journal of Clinical Oncology · 1994 · 78 citations

Oncology, Medicine, Dolasetron Mesylate +12